GLP-1 Drugs Reduce Stroke Risk by 17% in Type 2 Diabetes, Meta-Analysis Finds

What the researchers found

GLP-1 receptor agonists reduced adverse cerebrovascular outcomes by 17% (RR 0.83, 95% CI 0.76–0.91, I²=0%) across 28 RCTs with 74,148 patients. Specifically, ischemic stroke was reduced by 27% (RR 0.73, 95% CI 0.60–0.89) and the composite of ischemic stroke/TIA by 24% (RR 0.76, 95% CI 0.65–0.90). Nonfatal stroke was reduced by 15% (RR 0.85, 95% CI 0.76–0.94), but reductions in fatal stroke (RR 0.80) and hemorrhagic stroke (RR 0.92) were not statistically significant.

Benefits were statistically significant for dulaglutide and both subcutaneous and oral semaglutide. Patients with shorter diabetes duration and higher baseline kidney function (eGFR) showed greater benefit.

Why it matters

Stroke is a leading cause of death and disability in people with type 2 diabetes, who face double the stroke risk of the general population. Demonstrating that GLP-1 drugs specifically protect against ischemic stroke — not just cardiovascular events broadly — provides strong evidence for using these drugs in diabetes patients at cerebrovascular risk.

How the study worked

Systematic review and meta-analysis of 28 RCTs (≥24 weeks duration) in adults with type 2 diabetes, searching PubMed, Embase, Web of Science, Cochrane Library, and trial registries. Adjudicated cerebrovascular events were pooled using fixed-effects models. Subgroup analyses examined individual drugs, treatment duration, and baseline characteristics. Evidence quality was assessed using the GRADE framework.

What this study cannot tell us

Individual trial-level data were not available, limiting the depth of subgroup analyses. The lack of significant effect on fatal stroke and hemorrhagic stroke may reflect limited power for these rarer outcomes. Treatment duration and comparators varied across trials. The interaction analyses for baseline characteristics used P < 0.1, a liberal threshold.

How to read the evidence

This is a meta-analysis of 28 randomized controlled trials with zero heterogeneity (I²=0%), representing high-quality evidence. The GRADE framework was applied. The large sample size and consistent direction of effect across studies strengthen confidence in the findings.

When this study was published

Published in 2023, this meta-analysis includes trials through 2022 and represents the most comprehensive assessment of GLP-1 drugs' cerebrovascular effects at the time of publication.

The bigger picture

The cardiovascular benefits of GLP-1 drugs have been established, but their specific effects on stroke subtypes were less clear. This meta-analysis clarifies that the benefit is primarily ischemic (blood clot-related), not hemorrhagic (bleeding-related), which aligns with GLP-1 drugs' known anti-inflammatory and anti-atherosclerotic properties. This positions them as particularly valuable for stroke prevention in diabetes.

Questions still open

• What is the mechanism by which GLP-1 drugs protect against ischemic stroke — is it primarily through anti-atherosclerotic effects, blood pressure reduction, or direct neuroprotection?
• Would earlier initiation of GLP-1 therapy in diabetes maximize stroke prevention, given the greater benefit in patients with shorter diabetes duration?
• Do GLP-1 drugs reduce stroke risk in people without diabetes but with other cerebrovascular risk factors?

Common questions

Read the original research

GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

The Journal of clinical endocrinology and metabolism, 108(7), 1806-1812

Citation

Banerjee, Mainak; Pal, Rimesh; Mukhopadhyay, Satinath; Nair, Kirthana. (2023). GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. The Journal of clinical endocrinology and metabolism, 108(7), 1806-1812. https://doi.org/10.1210/clinem/dgad076